Prokidney Corp (PROK) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Prokidney Corp   (NASDAQ: PROK)


Prokidney's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Prokidney's ROI in the second quarter of 2026?
Prokidney Corp recorded a cumulative net loss of $-166 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -59.05%.

Within the Healthcare sector 523 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Jun 30 2026 quarter, so far to 3747, from total ROI ranking in the first quarter of 2026 at 4304.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM -28.56 % -27.31 % -20.92 % -14.63 % -6.08 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 226 268 306 323 344
Return On Investment (TTM) -59.05 % -50.4 % -45.07 % -44.1 % -41.86 %
PROK's Overall Ranking # 3747 # 4304 # 3784 # 3787 # 3789
Seq. Investment Change TTM -9.48 % -7.83 % -6.85 % -8.09 % -7.89 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -166 -156 -152 -159 -164

PROK Company Profile >> Back to PROK Roi Comparisons >> See Annual PROK Return On Investment



Return On Investment PROK's Ranking
Within: No.
Industry # 80
Sector # 524
Overall # 3747

Return On Investment Statistics
High Average Low
-2.13 %
-32.48 %
-59.05 %
(Mar 31 2022)   (Jun 30 2026)



  News about Prokidney Corp Return on Investment ROI

ProKidney Corp Raises $140 Million in Public and Direct Offering, Fueling Breakthroughs in Chronic Kidney Disease Therapeutics

June 17, 2024

ProKidney Corp Announces Successful Closing of $140 Million Public Offering and Registered Direct Offering
ProKidney Corp, a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease, has recently completed a significant financial milestone. The company has successfully closed a public offering and concurrent registered direct offering, raising a total of $140 million.
In the public offering, ProKidney sold 46,886,452 Class A ordinary shares to the public at a price of $2.42 per share. This includes an additional 4,142,232 Class A ordinary shares that were sold as a result of the underwriters exercising their option to purchase additional shares. The total value of the shares sold in the public offering, before applicable underwriting discounts and commissions, amounts to $113.5 million.

ProKidney's Strategic Leadership Appointments to Drive Clinical and Technical Excellence Amid Financial Challenges

March 25, 2024

ProKidney Strengthens Clinical and Technical Operations with Key Leadership Appointments
ProKidney, a prominent player in the healthcare sector, has recently announced significant leadership appointments aimed at bolstering its clinical and technical operations. Dr. Ulrich Ernst has joined the company as the Executive Vice President of Technical Operations, bringing with him extensive expertise in the field of process development and manufacturing of cell therapies. These strategic moves come at a time when ProKidney is facing challenges, with a decline in stock values and a cumulative net loss over the past year.
Dr. Ulrich Ernst s appointment as the Executive Vice President of Technical Operations is expected to fortify ProKidney s capabilities in process development and the manufacture of cell therapies. With a strong background in this domain, Dr. Ernst is well-equipped to drive innovation and efficiency in production processes, ensuring that ProKidney remains at the forefront of cell therapy advancements.





Financial Statements
Prokidney's II. Quarter Investments $ 226 Millions PROK's Balance sheet
Prokidney's II. Quarter Income $ -46 Millions Quarterly PROK's Income Statement
PROK's Income by Division See PROK's Income by Division


PROK Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 305 405 396 507 249
Y / Y Investment Growth -24.71 % 2.36 % -22.01 % 103.4 % -
Net Income in Millions -152 -163 -135 -148 -2
Y / Y Net Income Growth - - - - -
Annual Return On Investment -49.74 % -40.34 % -34.25 % -29.21 % -0.93 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Biotechnology & Pharmaceuticals Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
PROK's Roi Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for PROK's Competitors
Subscribers only: Roi for Prokidney's Suppliers
Subscribers only: Return On Investment for PROK's Customers

Other Ratios
PROK's Roa PROK's Inventory Turnover Ratio PROK's Growth Rates PROK's Dividend Statistics
PROK's Profitability Ratios PROK's Asset Turnover Ratio PROK's Dividend Growth
PROK's Roe PROK's Valuation Ratios PROK's Financial Strength Ratios PROK's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI

Date modified: 2026-09-12T06:25:36+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.